Skip to main content
Published locations for AUGMENT: Lenalidomide/Rituximab vs Placebo/Rituximab in Relapsed or Refractory Indolent Lymphoma
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
AUGMENT: Lenalidomide/Rituximab vs Placebo/Rituximab in Relapsed or Refractory Indolent Lymphoma
User login
Username
Password
Reset your password
/content/augment-lenalidomide/rituximab-vs-placebo/rituximab-relapsed-or-refractory-indolent-lymphoma
/jcomjournal/article/208643/hematology/augment-lenalidomide/rituximab-vs-placebo/rituximab-relapsed